Opinion|Videos|September 4, 2024
Clinical Insights on the Patient Presentation & Treatment Course
The panel shares their expert impressions of the case and deliberates on potential treatment strategies for the 53-year-old patient with heavily pre-treated multiple myeloma, considering his prior therapies and current clinical status.
Advertisement
Video content above is prompted by the following:
- Please describe your initial impressions of this case. How might you have treated or managed this patient in your clinical practice?
Advertisement
Related to this article
An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
2
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors
3
FDA Grants Fast Track Designation to SOT109 in Advanced Colorectal Cancer
4
Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026
5